Workflow
Intellectual Property
icon
Search documents
USPTO Files ISSUE NOTIFICATION for BetterLife's BETR-001 Composition of Matter Patent
Thenewswire· 2025-06-18 12:00
Core Viewpoint - BetterLife Pharma Inc. has received an ISSUE NOTIFICATION from the US Patent and Trademark Office for its BETR-001 composition of matter patent, which provides strong intellectual property protection until at least 2042 [1][4]. Patent and Intellectual Property - The patent covers various claims related to crystalline forms of BETR-001, its formulations, and isomers [3]. - The composition of matter patent is considered the strongest level of intellectual property coverage for a compound [4]. Product Development - BETR-001 is a non-hallucinogenic neuroplastogen aimed at treating psychiatric and neurological disorders, including depression, anxiety, PTSD, traumatic brain injury, migraines, and neuropathic pain [4][8]. - The company has completed most IND-enabling studies and plans to file for IND and start human trials in H1 2026 [5]. Financial and Shareholder Information - BetterLife has issued a total of 6,473,712 common shares and the same number of share purchase warrants, related to convertible debentures and accrued interest totaling $647,371 [6]. - The share purchase warrants are exercisable at an exercise price of $0.10 per warrant and have varying expiration dates [6]. Company Overview - BetterLife Pharma is focused on developing and commercializing compounds for neuro-psychiatric and neurological disorders, specifically BETR-001 and BETR-002 [7]. - BETR-002 is based on honokiol and is also in preclinical studies, targeting anxiety-related disorders [9]. - The company is exploring strategic alternatives for further development of a drug candidate for viral infections [10].
Why I’m letting AI write my next book | Deborah Chen | TEDxLondonBusinessSchool
TEDx Talks· 2025-06-16 16:40
I wrote my first book when I was 18. The publisher in China picked it up and somehow it became a hit. The sudden fame was quite over overwhelming as were the book royalties that I was getting paid.And then at a book signing, I was just sitting at a desk scribbling my name on book after book, thanking everyone who had kindly waited in line. And a guy came up. He was wearing those orange socks so bright that they could blind you.And he very cheerfully took out a book for me to sign. Except it wasn't my book. ...
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat
Globenewswire· 2025-05-27 05:00
Core Viewpoint - Vivoryon Therapeutics N.V. has been granted a new U.S. patent for its lead drug varoglutamstat, enhancing its intellectual property portfolio and supporting its development strategy in kidney disease [2][3][7]. Group 1: Patent Details - The newly granted U.S. composition of matter patent (US 12,312,335) covers the only polymorph of the salt form used in varoglutamstat, with a patent term extending through 2044 and potential extension to 2049 under the Hatch-Waxman Act [3][4]. - The patent was granted after an accelerated examination process, indicating the efficiency and effectiveness of the company's patent application strategy [2][3]. Group 2: Strategic Focus - Vivoryon is actively pursuing additional patents related to varoglutamstat and its applications in kidney disease, including medical use and dosing regimens, both as monotherapy and in combination with SGLT-2 inhibitors [4][5]. - The company has filed multiple patents in the past months, reflecting its commitment to strengthening its intellectual property in the field of kidney diseases [4][5]. Group 3: Broader Patent Portfolio - Vivoryon has developed a robust patent portfolio for QPCT/L inhibitors, encompassing over 20 patent families and more than 400 patent applications and issued patents across major markets [6]. - The majority of the patents focus on composition of matter for QPCT/L inhibitors, with recent applications emphasizing the company's focus on kidney diseases and the synergistic effects observed in preclinical research [5][6].
AmpliTech Group Reports Q1 FY2025 Results and Signals Positive Outlook with Record Bookings and Strategic IP Advancements
GlobeNewswire News Room· 2025-05-15 12:00
Core Insights - AmpliTech Group, Inc. reported its Q1 FY2025 financial results, showing a revenue of $3.6 million, a 57% increase compared to Q1 FY2024, marking the strongest quarterly performance since Q4 FY2023 [6] - The company has provided optimistic revenue guidance for FY2025, expecting at least $21 million in revenue, more than double the previous fiscal year's sales, supported by a record backlog of $19.6 million and significant customer demand [3][4] Financial Performance - Revenue for Q1 FY2025 reached $3.6 million, reflecting a 57% increase over Q1 FY2024 [6] - The company ended the quarter with $19.1 million in cash and receivables, $24.6 million in working capital, and zero debt, indicating a strong financial position [6] - AmpliTech has booked $12 million in firm orders from Letters of Intent totaling over $118 million, with all booked revenue scheduled for delivery in FY2025 [3] Strategic Initiatives - The company achieved major operational milestones in the first four months of FY2025, including securing the largest backlog in its history and enhancing its intellectual property portfolio [4] - AmpliTech's certified ORAN 5G radios are being deployed globally, with shipments to a Tier 1 MNO in Canada already underway [4] - The core division expanded its proprietary LNB product line targeting the satellite market, with projections indicating LNB revenues may match core LNA sales within 12 months [7] Market Position and Growth Outlook - AmpliTech is positioned for successive quarters of growth, with a healthy balance sheet and an expanding portfolio of proprietary 5G and satellite technologies [8] - The company continues to build its global brand presence through participation in key industry events, enhancing its market visibility [7]
New PatentVest Pulse Report Reveals IP Gaps in Billion-Dollar Humanoid Robotics Startups
Globenewswire· 2025-05-14 16:00
Core Insights - The PatentVest Pulse report highlights a significant gap between rising valuations of humanoid robotics startups and their lack of intellectual property protections, indicating potential long-term value risks [1][2] - The report serves as a strategic guide for investors, board members, and CEOs to identify which companies are well-positioned and which are vulnerable in the humanoid robotics sector [1][2] Industry Analysis - The analysis benchmarks the IP portfolios of leading startups such as Figure AI, Sanctuary AI, Apptronik, Tesla Optimus, Neura Robotics, Engineered Arts, 1X Technologies, and Collaborative Robotics, mapping over 11,000 patent families across 794 entities globally [3] - The report emphasizes the importance of IP as a critical factor for scaling, licensing, and capturing long-term value in the humanoid robotics industry [2] Emerging Leaders - Figure AI is gaining attention and capital, while Sanctuary AI is building a defensible platform, with other companies like Neura Robotics, Apptronik, and Agility Robotics also making strides through focused IP strategies [6] - Sanctuary AI is noted as one of the few startups among the top 20 global patent holders, highlighting the rarity of defensible positions in the industry [6] Corporate Landscape - Major industrial players such as Sony, UBTECH, Honda, Toyota, Hyundai, Alphabet, and Samsung hold over 11,000 humanoid robotics patent families, indicating significant corporate consolidation in the IP landscape [6] - University-led innovation is crucial, with institutions like Tsinghua University, AIST, and the University of Tokyo holding key patents that influence core technologies and future commercialization opportunities [6]
Cava Healthcare Appoints Barbara Sharp As Chief Executive Officer And As A Director
Thenewswire· 2025-05-08 21:00
Vancouver, British Columbia, May 8th, 2025 – TheNewswire - CAVA Healthcare Inc, (the “Company”) is pleased to announce the appointment of Barbara Sharp as its new Chief Executive Officer (CEO), effective immediately.  She has also been appointed to serve as a Director of the Company until next Annual General Meeting.Barbara brings a wealth of leadership experience across public, private, and nonprofit sectors, with a career spanning over three decades in executive management, labour relations, conflict res ...
Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure
Globenewswire· 2025-05-07 12:30
Core Insights - Orchestra BioMed is expanding its intellectual property portfolio, securing 10 new patents related to hypertension treatment, bringing the total to 120 patents in this area [2][6] - The company has also increased its patent estate for heart failure treatment to 17 issued patents, enhancing its overall IP platform [2][6] - AVIM therapy is currently being evaluated in the BACKBEAT global pivotal study for treating uncontrolled hypertension in patients indicated for pacemakers, highlighting its potential impact on broader cardiovascular health [2][8] Intellectual Property Expansion - The global intellectual property portfolio for AVIM therapy includes patent protection in key markets such as the United States, Europe, Japan, and China [3] - The hypertension-specific patent estate now consists of 46 issued U.S. patents and 91 patents outside the U.S., collectively comprising over 2100 claims related to hypertension and heart failure [6] Strategic Collaborations - Orchestra BioMed has a strategic collaboration with Medtronic for the development and commercialization of AVIM therapy, focusing on hypertension treatment in pacemaker-indicated patients [4] - The company is also partnered with Terumo for the development of the Virtue Sirolimus AngioInfusion™ Balloon for treating atherosclerotic artery disease [4] Regulatory Designations - AVIM therapy has received Breakthrough Device Designation from the U.S. FDA for treating uncontrolled hypertension with increased cardiovascular risk, which may expedite its development and market access [2][6][9]
ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System
Globenewswire· 2025-04-28 12:31
Core Insights - ReShape Lifesciences has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application related to an intragastric balloon system, which includes a swallowable capsule and a degradable release valve designed for natural excretion after deflation [1][2] - The patent, once issued, will provide protection until at least January 2031, potentially extending further with a Patent Term Extension [1] - The company has secured over 50 patents related to its intragastric balloon system since its initial application in 2011, resulting in a total of more than 160 patents issued and pending [2] Company Overview - ReShape Lifesciences is a leading company in the weight loss and metabolic health solutions sector, offering a range of products and services aimed at managing obesity and metabolic diseases [3] - The company’s FDA-approved products include the Lap-Band and Lap-Band 2.0 Flex Systems, which provide minimally invasive treatments for obesity, and the Obalon balloon technology, a non-surgical, swallowable intra-gastric balloon [3] Recent Developments - ReShape Lifesciences has entered into an asset purchase agreement with Biorad Medisys, under which it will sell substantially all of its assets, including the Lap-Band System and Obalon Gastric Balloon System, to Biorad [4]
中兴通讯已申请全球专利9.3万件 过去20年研发投入增长超10倍
Shen Zhen Shang Bao· 2025-04-27 16:52
Core Insights - The core viewpoint of the article highlights ZTE Corporation's significant investment in research and development (R&D) over the past 20 years, showcasing its commitment to innovation and intellectual property management [2][3] Group 1: R&D Investment and Strategy - ZTE has increased its R&D investment by over 10 times in the past 20 years, with R&D expenses projected to account for approximately 20% of revenue in 2024 [2] - By the end of 2024, ZTE will have applied for a total of 93,000 global patents, with 48.5% of its employees dedicated to R&D [2] - The company has established 11 R&D bases across the country, with over 40% of its employees holding a master's degree or higher [2] Group 2: Intellectual Property Achievements - ZTE has achieved patent coverage in 55 countries and regions globally, with 48,000 authorized patents and over 90% being invention patents [3] - The company has applied for approximately 5,500 chip-related patents and over 5,000 AI patents, with nearly 50% of the AI patents already authorized [3] - ZTE ranks among the top five global patent holders in terms of effective global patent families, having disclosed nearly 7,000 families of essential 5G standard patents [3] Group 3: Recognition and Awards - ZTE has received numerous accolades for its patent achievements, including 11 gold awards, 3 silver awards, and 39 excellence awards in the China Patent Awards, as well as 30 National Science and Technology Progress Awards [3] - The recognition reflects ZTE's systematic advantages in technology R&D, patent layout, and industrial application [3]
Innventure, Inc. to Present at April Intellectual Property Conferences in California
Globenewswire· 2025-03-25 12:30
Group 1 - Innventure, Inc. will host two events during the IP Leadership Executive Summit on April 15 and 16, and will also speak at the LES-SVC's 21st Annual Chapter Conference on April 17 [1][2] - The IP Leadership Executive Summit is a two-day forum focusing on the future of intellectual property and technology solutions, with Innventure as a platinum partner [2] - Innventure will conduct a workshop titled "Breaking Industry Boundaries: The Reimagined IP Commercialization Playbook" on April 15, allowing participants to explore unlocking value from technology innovations [3] Group 2 - A roundtable discussion titled "Maximizing Value: Where the Rubber (TIRE) Meets the Road" will also be held on April 15, moderated by Innventure's Vice-President of Strategic Partnerships, Brice Dubosq [4] - The LES Silicon Valley Chapter Conference will address trends and challenges in innovation and IP deal-making, with the theme "The Silicon Valley Deal Machine" [4] - Innventure is a gold sponsor of the event, with Executive Chairman Mike Otworth delivering a keynote speech on April 17 titled "Breaking Free: Unleashing Innovation Beyond Corporate Wall" [5] Group 3 - Innventure's Vice President of Business Development/Strategic Partnerships, Gayle Anderson, will participate in a panel discussion on "Scaling Success: Business Models to Scale-up and Scale-out" on April 17 [5] - The panel will focus on business models that support innovation and commercialization deal-making, particularly in the context of AI-driven hardware breakthroughs [6] - Innventure specializes in founding, funding, and operating companies focused on transformative technology solutions, aiming for a target enterprise value of at least $1 billion [6]